ADVENTRX To Present Thiovir Preclinical Data At The 20th International Conference On Antiviral Research

ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical company developing anticancer and
antiviral therapies, announced today that data from preclinical studies of
Thiovir(TM), a drug candidate in a new class of reverse transcriptase
inhibitors (RTIs), will be presented at the 20th International Conference
on Antiviral Research (ICAR) in Palm Springs, April 30 - May 4 2007. The
abstract entitled "Combinations of Thiovir and neuraminidase inhibitors
exert synergistic antiviral activity on human, equine and avian influenza
in vitro" will be presented on May 2, 2007.


"The ICAR data in avian influenza coupled with previously reported
preclinical results are convincing evidence for the importance of further
development and evaluation of this broad spectrum antiviral and novel
reverse transcriptase inhibitor in the treatment of influenza viruses,"
said Evan M. Levine, Chief Executive Officer of ADVENTRX. "We currently
plan to initiate a Phase I/II clinical trial of Thiovir in HIV positive
patients later this year."



About Thiovir (ANX-201)



Thiovir (ANX-201) is a pyrophosphate analogue, a new class of reverse
transcriptase inhibitor (RTI) designed for oral delivery as a component of
AZT- based highly active antiretroviral therapy (HAART). Thiovir is an
analogue of foscarnet that delivers both the active drug TPFA
(thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral
formulation. Thiovir is intended to deliver the benefits of the drug
foscarnet, including broad spectrum antiviral activity, with the added
benefit of improved cell permeability. ADVENTRX currently plans to initiate
a Phase I/II clinical trial of Thiovir in HIV positive patients in 2007.



About ADVENTRX Pharmaceuticals



ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing anticancer and antiviral
therapies that improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, toxicity,
bioavailability and resistance. The Company's lead product candidate,
CoFactor (ANX-510), currently is being tested in a pivotal Phase III study
for metastatic colorectal cancer in the US. More information can be found
on the Company's web site at adventrx.



Forward Looking Statement



ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. Such
forward-looking statements are made based on management's current
expectations and beliefs and should not be regarded as a statement or
representation by ADVENTRX that any of its plans, including its anticipated
milestones, will be achieved on time or at all. The potential risks and
uncertainties that could cause actual results to differ materially include,
but are not limited to: the risk that ADVENTRX will be unable to raise
sufficient capital to fund the projects necessary to meet its anticipated
or stated goals and milestones, including funding the continued development
of Thiovir(TM); the potential to attract a strategic partner for
Thiovir(TM) or any of ADVENTRX's other product candidates and the terms of
any related transaction; the ability to timely enroll subjects in
ADVENTRX's current and anticipated clinical trials, including the currently
planned Phase I/II clinical trial of Thiovir(TM); the results of planned
clinical trials for Thiovir(TM) or ADVENTRX's other product candidates; the
potential for Thiovir(TM) and ADVENTRX's other product candidates to
receive regulatory approval for one or more indications on a timely basis
or at all, and the uncertain process of seeking regulatory approval; other
difficulties or delays in developing, testing, manufacturing and marketing
of and obtaining regulatory approval for Thiovir(TM) or ADVENTRX's other
product candidates; the market potential for reverse transcriptase
inhibitors and other target markets, and ADVENTRX's ability to compete in
those markets; unexpected adverse side effects or inadequate therapeutic
efficacy of Thiovir(TM) or ADVENTRX's other products candidates that could
delay or prevent regulatory approval or commercialization, or that could
result in recalls or product liability claims; the risk that preclinical
and clinical results are not indicative of the success of subsequent
clinical trials and that products will not perform as preclinical and
clinical data suggests or as otherwise anticipated; the potential for
regulatory authorities to require additional preclinical work or other
clinical requirements to support regulatory filings; the scope and validity
of patent protection for Thiovir(TM) and ADVENTRX's other product
candidates; and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at sec.
















You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. All forward-looking
statements are qualified in their entirety by this cautionary statement and
ADVENTRX assumes no obligation to revise or update any forward-looking
statement, including as set forth in this press release, to reflect events
or circumstances arising after the date on which it was made.


ADVENTRX Pharmaceuticals, Inc.

adventrx/